| Progressive systemic scleroderma is an autoimmune
disorder of the connective tissue leading to slowly
progressive fibrosis and later to sclerosis. Subsequently
patients suffering from scleroderma develop tight skin
and manifest involvement of the heart, kidneys and
lungs. Scl-70 antibodies are directed against the enzyme
DNA Topoisomerase I and are highly specific for
scleroderma (> 90%). Patients with anti-Scl-70 antibodies
are more likely to have facial skin involvement
and tend to develop manifestation of the heart, kidneys
and lungs in comparison with anti-Scl-70 antibodies
negative scleroderma patients. |
|
|
 |
 |
|
| Tests |
12 x 8 Tests |
|
|
|
|
| Calculation |
quantitative |
|
|
|
|
| Range |
0 – 200 U/ml |
|
|
|
|
| Cut-off |
25 U/ml |
|
|
|
|
| Sensitivity |
1 U/ml |
|
|
|
|
| Calibration |
CDC |
|
|
|
|
| Substrate |
TMB / 450 nm |
|
|
|
Instruction for Use: ORG 512-0508-01-gb.pdf
Material-Safety-Datasheet: ORG 512.pdf